COPD is associated with multiple comorbidities such as cardiovascular diseases, depression, and diabetes mellitus. Bronchodilators are often used in the management of COPD, but can also have an effect on comorbidities. We were delighted to talk with editorial board member Professor Mario Cazzola (University of Rome ‘Tor Vergata’, Rome, Italy) to learn more around these comorbidities and the impact bronchodilators may have.
‘What’s New in COPD Pharmacology’ was presented at CHEST Congress 2022, 27-29 June 2022.
Questions
- What are the known comorbidities of COPD? (0:41)
- What are the potential effects of bronchodilators on the comorbidities of COPD? (2:15)
- Given these potential effects of bronchodilators, to what extent are the comorbidities of COPD not true comorbidities but instead the consequence of concomitant pharmacologic treatments? (6:12)
Disclosures: Mario Cazzola has nothing to disclose in relation to this video interview.
Support:Â Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the CHEST meeting 2022.
